Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: EntroGen KRAS, NRAS Mutation Analysis Kits


EntroGen this week announced the availability of expanded colorectal cancer screening products.

EntroGen K-Ras and N-Ras Mutation Analysis kits have been updated to include coverage for exon 2, 3, and 4 mutations in both genes. The company has obtained a CE IVD mark for these products.

The importance of mutations in exons 3 and 4 of KRAS and 2, 3, and 4 of NRAS were demonstrated in a randomized, multicenter phase 3 study published in 2013, where researchers from Amgen identified them as markers of innate resistance to Vectibix (panitumumab) in addition to the already known exon 2 mutations in KRAS.

Following the publication of this study, Amgen issued new guidelines for prescribing this drug for treatment of metastatic colorectal cancer. The newly expanded real-time PCR kits now cover all known mutations in codons 12, 13, 59, 61, 117, and 146 of the KRAS and NRAS genes, as well as the BRAF V600E mutation, providing a comprehensive screening tool that has superior sensitivity and turnaround time than those offered by NGS platforms, EntroGen said. The products have been validated on various real-time PCR instrument models, the company added.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.